Pharmaceutical Technology
MAY 2, 2023
The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.
Cloudbyz
MARCH 5, 2024
Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability. The conditions affecting the living system can influence the final product, making the manufacturing process more sensitive and challenging.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 9, 2022
A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. The early-stage study, sponsored by the drug’s manufacturer Replimune, is testing the safety and dosage of RP2, as well as evaluating its ability to shrink tumours.
Advarra
JANUARY 11, 2024
Additionally, personalized medicine tends to be more difficult to manufacture because of regulatory requirements beyond traditional drug manufacturing requirements. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.
pharmaphorum
AUGUST 23, 2021
Ahmedabad-based Zydus Cadila has said it expects to launch ZyCoV-D in late September or early October, and expects to be able to manufacture around 100-120 million doses a year, with around 10 million available at launch. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
The Pharma Data
DECEMBER 16, 2020
Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed. About Novavax.
XTalks
NOVEMBER 23, 2020
Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. As a manufacturing partner for Oxford’s vaccine, AstraZeneca is ramping up its production capabilities as it plans to make up to three billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
Expert insights. Personalized for you.
130 
Let's personalize your content